Featured
Last news
CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement
BEIJING, CHINA / ACCESS Newswire / May 7, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it has received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") dated May 5, 2025 stating that the Company is not in compliance with the requirement to maintain a minimum Market Value of Listed Securities ("MVLS") of $35 million as set forth under Nasdaq Listing Rule for continued listing on The Nasdaq Capital Market.
Interactive Strength Inc. (Nasdaq:TRNR) Provides Shareholder Update on Sportstech's Strong April 2025 and LTM Performance
Sportstech Announced Strong Results, with April 2025 revenue growth at 36% YOYCurrent FX rates indicate that the LTM figures would be approximately $54M in Revenue and $5M in EBITDA through April 2025Strong Business Momentum, Revenue and Positive EBITDA Underscore Target's Operational Strength and Logic of Acquisition in advance of Closing
Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments
Gates Foundation supports Evotec with a $ 2.5 M grant to generate critical data supporting development of next generation tuberculosis drug combinations.The collaboration continues a successful partnership on evaluating new treatment regimens aimed at reducing treatment duration and overcoming resistance to current therapies.
Motown legend Smokey Robinson sued for sexual assault
Motown legend Smokey Robinson was facing a multimillion dollar lawsuit on Tuesday from four former housekeepers who allege the soul singer repeatedly raped and sexually assaulted them.
Israel's plan for Gaza draws international criticism
Israel drew international condemnation on Tuesday over its plans for an expanded Gaza offensive, as the country's far-right finance minister called for the Palestinian territory to be "destroyed".
Top US court allows Trump's ban on trans troops to take effect
A divided US Supreme Court on Tuesday allowed President Donald Trump's ban on transgender military personnel to take effect while litigation proceeds, putting thousands of troops at risk of dismissal.
Sudan cuts ties with UAE, accused of backing paramilitaries
Sudan's army-aligned government on Tuesday severed diplomatic ties with the United Arab Emirates, accusing the Gulf state of supplying weapons used by the rival paramilitaries to strike its de facto capital.
'Wagatha Christie': Vardy and Rooney settle on legal costs
The years-long libel battle between England footballer wife Rebekah Vardy and Coleen Rooney drew to a close on Tuesday with a specialist UK court ordering Vardy to pay some £1.4 million to her rival.
Move over Met Ball. For fashion wow head to the Vatican
Forget feathers, fringe and sparkles. But if bold and brash colour is your thing, look no further than the conclave at the Vatican.
Cardinals to move into Vatican on eve of conclave
Cardinals will on Tuesday begin moving into the Vatican accommodation where they will stay during the conclave, on the eve of their historic, secretive meeting to elect a new pope.
How a privately owned city in Kenya took on corrupt officials
To many, Tatu City on the outskirts of Nairobi looks like a success.
Australian mushroom murder suspect rejected help preparing meal: witness
An Australian woman accused of murdering three people with a toxic mushroom-laced lunch rejected offers of help before serving the dish, the sole guest to survive the deadly meal told a court on Tuesday.
Prayers, pride in Philippine papal contender's hometown
Philippine Cardinal Luis Antonio Tagle may be one of the favourites to be named the next pope, but a Catholic Sister who has known him for half a century says she will never pray for it to happen.
Mosaic Announces First Quarter 2025 Results
TAMPA, FL / ACCESS Newswire / May 6, 2025 / The Mosaic Company (NYSE:MOS) released its financial results for the first quarter of 2025. The company's earnings release and supplemental materials are available at https://investors.mosaicco.com/financials/quarterly-results.
Mosaic Biosciences Launches Neptunion in China
TAMPA, FL / ACCESS Newswire / May 6, 2025 / The Mosaic Company (NYSE:MOS) is advancing its strategy to redefine growth, and is proud to announce a successful biostimulant product launch in China. Neptunion is our newest biostimulant product - it helps crops address abiotic pressures such as drought, salinity and heat by adding stress resistant properties into water soluble fertilizers. Our Mosaic Biosciences product line offers sustainable ag technology to enable growers to improve yields while minimizing environmental impacts.
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update
Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1stConference call to be held June 2nd at 8AM EDT to discuss rusfertide data presented at ASCOFull dataset from Phase 3 ICONIC-LEAD trial with icotrokinra in patients with moderate-to-severe plaque psoriasis (PsO) presented at the 2025 AAD Meeting in March; data from adolescent subset presented at World Congress of Pediatric Dermatology in AprilPositive top line results from icotrokinra Phase 2b ANTHEM trial in moderately to severely active ulcerative colitis (UC) announced in March, data to be presented at medical conference later in 2025Cash, cash equivalents and marketable securities of $697.9 million as of March 31, 2025, anticipated to provide cash runway through at least end of 2028
The Dixie Group 2025 Q1 Earnings Release and Conference Call
DALTON, GA / ACCESS Newswire / May 6, 2025 / You are invited to participate in a conference call with the management of THE DIXIE GROUP, INC (OTCQB:DXYN) regarding results for 2025 First Quarter Earnings Release on Friday, May 9, 2025, at 10:00 a.m. Eastern Time.
CannapharmaRx Continues into New European Market with First Shipment Completed to Germany
CALGARY, AB / ACCESS Newswire / May 6, 2025 / CannaPharmaRX, Inc. (OTC PINK:CPMD), a future leader in cannabis cultivation, is pleased to share recent updates, including its latest cultivation activities and sales achievements.
Electronic Caregiver Launches First-Ever AI-Powered Virtual Care Ecosystem Featuring Interactive Avatar, Now Available via Athenahealth’s EHR Network
Addison Care delivers the industry's most comprehensive AI-enabled chronic care platform - offering vitals monitoring, automated wellness checks, caregiver support, and integrated TeleCare services - now accessible to thousands of clinics through Athenahealth's nationwide EHR ecosystem.
Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025
WOBURN, MA / ACCESS Newswire / May 6, 2025 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three months ended March 31, 2025 on Thursday, May 15, 2025. The results will be released after the market close on Thursday, May 15 and the company will host a conference call on Friday, May 16 at 10:00am Eastern Time.
Introducing the New SHELLPHA Series Ergonomic Mice, Designed for Comfort and Connectivity for a Modern Workspace
The new SHELLPHA series features multi-device connectivity with Bluetooth and USB wireless for a cleaner, more connected workspace.
SOHM, Inc., Unveils Genetically Engineered Ovarian Cancer Cell Line Using ABBIE(TM) Platform to Accelerate GYS1 Drug Discovery
CHINO HILLS, CALIFORNIA / ACCESS Newswire / May 6, 2025 / SOHM, Inc. (OTC PINK:SHMN), a biotech company at the forefront of precision cellular engineering, announced today the successful development of a genetically modified ovarian cancer cell line (SKOV3) overexpressing the GYS1 gene, using its proprietary gene editing platform, ABBIE™. This breakthrough establishes a powerful tool for the rapid screening of novel glycogen synthase 1 (GYS1) inhibitors and underscores SOHM's capacity to swiftly generate custom-engineered cell models to support targeted drug development.
Clarity Clinic Expands PHP/IOP Mental Health Services to Arlington Heights, Bringing Specialized Care to the Northwest Suburbs
New Adult and Adolescent Programs Launching in May and June to Improve Access to Structured Mental Health Support
Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market
FORT LAUDERDALE, F / ACCESS Newswire / May 6, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched Lurasidone, a new generic prescription drug in the therapeutic class of antipsychotics.
Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization
New analysis suggests efficacy of Xifaxan to mitigate OHE rehospitalizations irrespective of treatment history
CBD Life Sciences Inc. (CBDL) Announces New Manufacturing Deal With A Southwest-Based Company
Strategic alliance positions CBDL for aggressive national growth through 100+ retail locations and new premium product lines
SafeHeal(R) Closes Oversubscribed €35 Million Series C Equity Financing
Financing led by Solar Eclipse with new investors Gideon Strategic Partners and M&L Healthcare, part of M&L Group, and returning investors Sofinnova Partners and one of the largest Multinational life sciences corporations from a strategic standpoint.Proceeds will support the completion of SafeHeal's IDE pivotal study and preparation for commercial launch of their lead technology, Colovac®.
MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity
Preclinical data supports the advancement of oral Ketamir-2 as a safe, next-generation alternative to ketamine, with ongoing momentum in Phase I clinical trial enrollment
Global Survey Reveals Urgent Gaps in Awareness, Access, and Treatment for Hepatitis D
LONDON, UK / ACCESS Newswire / May 6, 2025 / A new report released today by the World Hepatitis Alliance (WHA) reveals widespread knowledge gaps, inequities in access, and critical systemic barriers impeding the global fight against hepatitis delta.
FBC Holding, Inc. (FBCD) Expands Retail Footprint With Two Flagship Locations In Arizona's Top Shopping Destinations
SCOTTSDALE, AZ / ACCESS Newswire / May 6, 2025 / FBCD (OTC PINK:FBCD) is proud to announce a bold new leap in its expansion strategy, officially opening two premium retail locations at Chandler Fashion Center (3111 W Chandler Blvd, Chandler, AZ 85226) and SanTan Village (2218 E Williams Field Rd, Gilbert, AZ 85295). These launches position FBCD's retail presence at the heart of Arizona's most trafficked and trend-forward shopping destinations, reinforcing its growing dominance in the luxury streetwear and lifestyle market.
Boditech Med and SphingoTec Announce Launch of AFIAS penKid(R) Assay for Kidney Function Diagnostics
Boditech Med and SphingoTec announce the launch of the AFIAS sphingotest® penKid® assay, a diagnostic tool designed to aid in kidney function assessment for critically ill patients.The IVDR-marked assay provides quantitative measurements of Proenkephalin A 119-159 (penKid), supporting clinical decision-making in acute and critical care.This launch follows a licensing agreement granting Boditech the rights to develop and commercialize penKid-based assays, as well as a market development agreement between the two companies.
Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment
Group revenues of € 200 m, on track towards guidance; Shared R&D with similar trend as 2024; Just - Evotec Biologics with continuing growth momentumStrong progress in strategic protein degradation partnership with Bristol Myers SquibbStrategy building on technology and science leadership: Focus on high-growth, high-value segments, simplifying the business model and fostering operational excellence2025 Guidance and 2028 Outlook confirmed